Stereotactic Body Radiation Therapy (SBRT) Versus Radiofrequency Ablation (RFA) for Unresectable Colorectal Cancer Hepatic Metastases: A Cost-Effectiveness Analysis

Кириченко, В. М.; Thai, Ngoc; Parda, David S.

doi:10.1016/j.ijrobp.2016.06.394

International Journal of Radiation Oncology*Biology*Physics

2016

DOI: 10.1016/j.ijrobp.2016.06.394

|View full text |Cite

Stereotactic Body Radiation Therapy (SBRT) Versus Radiofrequency Ablation (RFA) for Unresectable Colorectal Cancer Hepatic Metastases: A Cost-Effectiveness Analysis

В. М. Кириченко¹,

Ngoc Thai

David S. Parda

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…External-beam radiotherapy is an attractive modality of HCC treatment. Advantages of radiation therapy include its non-invasiveness, patient convenience, low cost, and effectiveness (8)(9)(10)(11)(12)(13). In the United States, stereotactic body radiotherapy (SBRT) is one of the most popular forms of liver-directed radiotherapy for HCC (14,15).…”

mentioning

confidence: 99%

Outcomes of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Severe Cirrhosis and Ineligibility for Transplant

2018

View full text Add to dashboard Cite

Background/Aim: Our study reviewed the results of patients with hepatocellular carcinoma and Child-Pugh score 8-11 cirrhosis treated with stereotactic body radiotherapy when liver transplant was not an option. Patients and Methods: A retrospective review was performed on 15 patients with Child-Pugh class B and C cirrhosis treated with stereotactic body radiotherapy. The median total dose was 35 Gy in 4-5 fractions. None were listed for a liver transplant due to either being outside of the Milan criteria or to medical contraindications. Results: The overall survival was 26.7% at 6 months, with a mean survival of 152 days. The mean survival with and without ascites was 3.3 months and 8.3 months, respectively. Conclusion: For hepatocellular carcinoma with cirrhosis of Child-Pugh score 8 or more, prognosis after liver stereotactic body radiotherapy was suboptimal. While irradiation achieved local tumor control, progressive cirrhosis was a common cause of death. Patients without ascites at the time of radiotherapy had the best prognosis.

show abstract

mentioning

confidence: 99%

Outcomes of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Severe Cirrhosis and Ineligibility for Transplant

2018

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Stereotactic Body Radiation Therapy (SBRT) Versus Radiofrequency Ablation (RFA) for Unresectable Colorectal Cancer Hepatic Metastases: A Cost-Effectiveness Analysis

Cited by 1 publication

References 0 publications

Outcomes of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Severe Cirrhosis and Ineligibility for Transplant

Outcomes of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Severe Cirrhosis and Ineligibility for Transplant

Contact Info

Product

Resources

About